Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.

Mother and newborn © Arne Hoel World Bank

Febrile illness is the most common reason for childhood healthcare visits globally, with hundreds of millions of cases of fever in 0 to four-year-olds presenting at health facilities every year. Historically, in malaria-endemic countries it was assumed that malaria was the cause of fever, but with the advent of rapid diagnostic tests (RDTs) for malaria, combined with intensified malaria control activities over the last decade, the incidence rate of malaria has been substantially reduced. Health workers and researchers have noted that once malaria is ruled out, it is difficult to diagnose febrile illness due to limited diagnostic tools, laboratory facilities and the scarcity of comprehensive surveillance networks in low-resource settings. Thus, patients with fever are often misdiagnosed and given inappropriate treatments, such as antibiotics in the absence of a confirmed diagnosis, which in addition to mistreating individual patients may contribute to antimicrobial resistance.

Today, the ongoing pandemic of COVID-19, a disease with a potential presentation of non-specific febrile illness, further highlights the need for accurate diagnostics, strong surveillance networks and standardized data to efficiently handle this disease alongside addressing the multitudes of causes of potentially co-existing non-malarial febrile illnesses.

In order to map the main causes of fever in all malaria-endemic regions, researchers associated with the WorldWide Antimalarial Resistance Network (WWARN); the Infectious Diseases Data Observatory (IDDO) at the University of Oxford, the Foundation for Innovative New Diagnostics (FIND), London School of Hygiene & Tropical Medicine (LSHTM), University of Otago, University of Hong Kong, Fundação Oswaldo Cruz (Fiocruz), and the MORU Tropical Health Network - Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) and Cambodia-Oxford Medical Research Unit (COMRU) screened more than 100,000 articles published between 1980 and 2015 to provide the most comprehensive data available to date.

Read the full story on the IDDO website

Similar stories

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU OUCRU-Nepal Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.